Novo Nordisk A/S (Novo Nordisk A/S) LT-Debt-to-Total-Asset : 0.07 (As of Dec. 2023)

View and export this data going back to 1981. Start your Free Trial

What is Novo Nordisk A/S LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Novo Nordisk A/S's long-term debt to total assests ratio for the quarter that ended in Dec. 2023 was 0.07.

Novo Nordisk A/S's long-term debt to total assets ratio declined from Dec. 2022 (0.10) to Dec. 2023 (0.07). It may suggest that Novo Nordisk A/S is progressively becoming less dependent on debt to grow their business.

Novo Nordisk A/S LT-Debt-to-Total-Asset Historical Data

The historical data trend for Novo Nordisk A/S's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novo Nordisk A/S LT-Debt-to-Total-Asset Chart

Novo Nordisk A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.02

0.07

0.10

0.07

Novo Nordisk A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.10	0.10	0.07	0.07	0.07

Novo Nordisk A/S LT-Debt-to-Total-Asset Calculation

Novo Nordisk A/S's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	3003.453	/	46012.466
	=	0.07

Novo Nordisk A/S's Long-Term Debt to Total Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (Q: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (Q: Dec. 2023 )	/	Total Assets (Q: Dec. 2023 )
	=	3003.453	/	46012.466
	=	0.07

Novo Nordisk A/S (NYSE:NVO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Novo Nordisk A/S LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Novo Nordisk A/S's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Novo Nordisk A/S (Novo Nordisk A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novo Nordisk A/S (NYSE:NVO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

NONOF:USA NOVOB:Mexico NVO:Mexico NOVOBc:UK 0QIU:UK NOVO B:Denmark NOV:Germany NOV:Germany NOVA:Germany NOV:Germany NOV:Germany NOVA:Germany N1VO34:Brazil NNO2:Austria

Address

Novo Alle 1, Bagsvaerd, DNK, DK-2880

Website

https://www.novonordisk.com

With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting roughly 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.